Axoltis reports further Phase 2 data for ALS drug candidate NX210c

Axoltis Pharma has reported additional Phase 2 findings for NX210c in amyotrophic lateral sclerosis (ALS), including biomarker and clinical data from the SEALS trial.

Biomarker findings suggest target engagement

The additional findings from the SEALS trial, presented at the Society for Neuroscience’s Neuroscience 2026 meeting, include four-month follow-up data, analyses of clinical endpoints and predictive modelling using digital twins.

NX210c is a cyclic peptide being developed by Axoltis for neurodegenerative and trauma-related disorders. The candidate is designed to support blood-brain barrier repair and neuroprotection.

Biomarker analyses showed changes consistent with target engagement and potential stabilisation of the neurovascular unit. After four weeks of treatment, patients receiving the 10 mg/kg dose demonstrated a statistically significant reduction in plasma claudin-5 compared with placebo (p=0.0005).

The company also reported reductions in plasma matrix metalloproteinase-9 (MMP-9) activity, homocysteine and cerebrospinal fluid (CSF) S100β, biomarkers associated with blood-brain barrier function.

Changes in serum neurofilament light chain (NfL), a biomarker of neuronal injury, did not reach statistical significance at Week 6. However, a dose-dependent trend became more apparent at Weeks 10 and 16.

Four-month follow-up shows potential reduction in functional decline

At four months, NX210c continued to demonstrate a favourable safety and tolerability profile.

Analysis of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) showed that functional decline was reduced by an average of 0.51-0.58 points per month in the two treatment groups compared with placebo, representing a 32-36% reduction.

Patients receiving NX210c also experienced less deterioration in quality of life, measured using the ALSAQ-40 questionnaire, while assessments of muscle strength showed generally smaller reductions across several muscle groups.

Further analysis examined whether baseline NfL levels could help identify patients more likely to respond.

Of the 82 participants enrolled, 69.5% had baseline NfL levels of 95 pg/mL or below. In this subgroup, the monthly ALSFRS-R decline was -1.32 points in the placebo group, compared with -0.77 points for patients receiving 5 mg/kg and -0.53 points for those receiving 10 mg/kg.

These results represented reductions in the rate of functional decline of 42% and 60%, respectively, compared with placebo. The difference for the 10 mg/kg group approached statistical significance (p=0.062).

Patients with baseline NfL levels above 95 pg/mL showed a smaller or no apparent treatment effect.

Digital twin analysis supports further investigation

Axoltis also presented predictive modelling using digital twins to assess the potential treatment effect on functional decline.

Researchers used the PRO-ACT database of ALS patients to generate individualised placebo simulations for NX210c-treated participants. These models predicted how each patient’s disease progression might have developed without treatment.

Comparisons between treated patients and their simulated placebo counterparts showed reductions in the median monthly ALSFRS-R decline of 47% in the 5 mg/kg group (p=0.098) and 49% in the 10 mg/kg group (p=0.016).

An augmented placebo group, combining 20 trial participants receiving placebo with 62 simulated placebo patients, was also used for further comparisons.

In participants with baseline NfL levels of 95 pg/mL or below, the median monthly rate of functional decline was -0.29 points among NX210c-treated patients, compared with -1.24 points in the augmented placebo group (p<0.001). This represented an approximately 77% reduction.

No significant effect was observed in patients with higher baseline NfL levels.

“These additional findings suggest that baseline NfL levels may help identify patients more likely to benefit from NX210c treatment,” said Dr Annette Janus, chief medical officer at Axoltis Pharma.

The company said the combined safety, biomarker, clinical and modelling findings support continued development of NX210c, with dose selection and repeat-dosing regimens to be evaluated in a planned Phase 2b/3 study.

The SEALS trial enrolled 82 patients across 16 sites in France between November 2024 and November 2025. Participants received NX210c at either 5 mg/kg or 10 mg/kg, or placebo, through intravenous infusions three times weekly for four weeks. Nearly all continued receiving riluzole as background standard-of-care treatment.

Axoltis expects to report the full SEALS Phase 2 results by the end of 2026.

Mail Icon

news via inbox

Sign up for our newsletter and get the latest news right in your inbox